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Introduction: Contrast-induced nephropathy is a result of injury to the proximal tubules caused by 
oxidative stress and ischemia. Metabolomics is a novel technique that has been used to identify 
renal damage from drug toxicities. The objective of this study is to analyze the metabolic changes in 
the urine after dosing with intravenous (IV) contrast for computed tomograph (CT) of the chest 
Methods: A convenience sample of patients undergoing a chest CT with IV contrast who had at 
least one of the following: age ≥50 years, diabetes, heart failure, chronic kidney disease, coronary 
artery disease, or diastolic blood pressure >90 mmHg -- were eligible for enrollment. Urine samples 
were collected prior to imaging and 4-6 hours post imaging. Samples underwent gas chromography/
mass spectrometry profiling. We measured peak metabolite values and log transformed data. Paired 
T tests were calculated. We used significance analysis of microarrays (SAM) to determine the most 
significant metabolites. 
Results: The cohort comprised 14 patients with matched samples; 9 /14 (64.3) were males, and the 
median age was 61 years (IQR 50-68). A total of 158 metabolites were identified. Using SAM we 
identified 9 metabolites that were identified as significant using a delta of 1.6. 
Conclusion: Changes in urinary metabolites are present soon after contrast administration. This change 
in urinary metabolites may be potential early identifiers of contrast-induced nephropathy and could 
identify patients at high-risk for developing this condition. [West J Emerg Med. 2014;15(2):152–157.]
INTRODUCTION
Contrast-induced nephropathy (CIN) is the third leading 
cause of acute renal failure in hospitalized patients. Although 
the exact mechanism for the development of CIN is unknown, 
data support that factors involved in the process may include 
direct toxicity to the renal tubular epithelium, oxidative stress, 
ischemic injury and tubular obstruction.1 The increasing 
number of indications for the use of computed tomography 
(CT) with contrast in the emergency department (ED) has 
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led to concerns that the incidence of contrast- induced 
nephropathy may increase. It has been reported that the use 
of contrast-enhanced CT has increased over 200% in the last 
decade. 2 Studies have reported that the risk for CIN is highest 
is patients with heart failure, diabetes, prior renal failure, 
hypertension, and increasing age.3 Unfortunately, there are 
currently no methods to identify subjects at risk for CIN; 
therefore, these patients are only identified after they develop 
signs of acute kidney injury, which in many cases (such as 
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in chronic kidney disease patients) leads to the progression 
toward end stage renal disease. 
 Recent advances in the use of metabolomics have 
allowed the identification of specific metabolite patterns 
or profiles associated with acute kidney injury. Metabolic 
profiling refers to the measurement of a group of small 
molecule metabolites that reflect cellular responses to 
organ injury. In particular, using high performance liquid 
chromatography (HPLC) and gas chromatography (GC) 
coupled to mass spectrometry has allowed the quantification 
and identification of these metabolites. 
We hypothesize that patients who are prone to CIN have 
a metabolic change that predisposes them to CIN soon after 
contrast administration; if this is the case, metabolomics is 
an ideal mechanism for the early identification of patients 
at risk of developing CIN as it allows the identification of 
the multiple markers of injury. However, the first step in 
proving this hypothesis is to determine that a metabolomic 
change occurs after intravenous contrast administration. 
We therefore completed a pilot study evaluating changes 
in urinary metabolites before and after intravenous contrast 
administration in a high-risk group of patients for developing 
contrast-induced nephropathy. The specific aim was to identify 
urine metabolites that change after IV contrast administration. 
METHODS
This is a pilot study of prospectively identified patients 
undergoing a CT of the chest with intravenous contrast during 
their ED evaluation. The institutional review boards at all 
participating centers approved this study.
Study Setting and Selection of Participants
 A convenience sample of patients was enrolled. To 
be eligible for the study, patients had to be >18 years old, 
undergoing CT angiography of the chest and have at least 
1 of the following high-risk features for CIN: Diabetes,4-5 
coronary artery disease,3 congestive heart failure,4,6 chronic 
kidney disease (baseline creatinine >1.5mg/dl or GFR <60 ml/
min/1.73 m2.7 Additionally, patients must have been given a 
physician assessment of >75% likelihood of hospital admission. 
All patients received between 110 and 130 mL of non-ionic 
radiocontrast (Omnipaque 350, GE Healthcare Inc., Princeton, 
NJ ), delivered via automated timing injector into an arm vein.
 We excluded patients from the study if they had an 
estimated GFR <15 mls/min/1.73m2, a history of organ 
transplantation, were currently on immunosuppressive 
medications, were septic or on antibiotic therapy, had a history 
of, or were currently receiving dialysis of any type, or had an 
exposure to iodinated radiocontrast within 3 days prior to the 
study.
Data Collection and Processing
After a patient was identified as fulfilling inclusion 
and exclusion criteria, and informed consent was obtained, 
we collected data prospectively. This included race, 
demographics, dietary history, medical history, and physical 
examination. Additionally, electrocardiogram (ECG) findings 
as documented by the treating emergency physician were 
recorded. Medical history was confirmed through patient 
self-report and review of the medical record when available. 
Medications administered in the ED and before arrival were 
also recorded. The final ED diagnosis was recorded and based 
on the treating physician’s impression. No laboratory tests 
were mandated as part of the trial study. Laboratory tests and 
chest radiography findings, as documented by a board-certified 
radiologist, were obtained from the medical record.
Urine samples were collected as a midstream sample or 
via a foley bag if one was already in place at the time of study 
enrollment. Urine samples were collected prior to imaging 
and 4-6 hours post imaging. Samples were divided into 2 ml 
aliquots and frozen at -80°C. We compared each patient’s pre-
CT urine peak metabolite levels to their own individual post-CT 
urine peak metabolite levels.
We followed all patients by chart review throughout their 
index stay to document in-hospital events. Serum creatinine 
levels were recorded at presentation, 24 and 48 hours.
GC-MS Analysis
Urine samples require no preparation prior to freezing. 
Neat urine samples were lyophilized without further 
pretreatment. To the dried samples, we added 20 μl of 
40 mg/ml methoxylamine hydrochloride in pyridine, and 
samples were agitated at 30°C for 30 min. Subsequently, 
180 μl of trimethylsilylating agent N-methyl-N-
trimethylsilyltrifluoroacetamide (MSTFA) was added, and 
samples were agitated at 37°C for 30 min. GC–MS analysis 
was performed using a Agilent 6890 N gas chromatograph 
(Atlanta, GA, USA) interfaced to a time-of-flight (TOF) 
Pegasus III mass spectrometer (Leco, St. Joseph, MI, USA).8-10 
Automated injections were performed with a programmable 
robotic Gerstel MPS2 multipurpose sampler (Mülheim an 
der Ruhr, Germany). We performed initial peak detection and 
mass spectrum deconvolution with ChromaTOF software 
(version 2.25, Leco), and later exported samples to the 
netCDF format for further data evaluation with MZmine and 
XCMS. We identified samples with >50% certainty. If this 
degree of certainty was not met they were given the name 
(unknown) followed by a numeric number. 
Statistical analysis
We presented continuous data as medians and interquartile 
range (IQR). The statistical analysis was performed on 
(natural) log-transformed peak concentration data to 
account for increases in the data variance that can occur. 
We performed paired T-test to determine differences in the 
metabolites with a p-value threshold of <0.05 mg. We used 
SAM, which assigns a score to each metabolite on the basis 
of change in metabolite expression relative to the standard 
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deviation of repeated measurements, to determine the most 
significant metabolites. For metabolites with scores greater 
than an adjustable threshold, SAM uses permutations of 
the repeated measurements to estimate the percentage of 
metabolites identified by chance, the false discovery rate 
(FDR). This adjustable threshold is determined by a tuning 
parameter (delta). The optimal delta was selected based on 
the target identification of 10 significant metabolites. (Table 
1) We performed statistical analysis using MetaboAnalyst 
(Canada).11 
RESULTS
The cohort comprised 14 patients with matched samples 
pre and post CT; 9 were males (64.3%) and the median age 
was 61 years (IQR 50-68). A majority of the patients had a 
history of hypertension 11 (78.6). There was no difference 
between the creatinine values at pre-CT compared to 24 or 48 
hours. The most common final diagnosis was chest pain not 
otherwise specified. The median time from the last food intake 
in these patients was 11.2 (IQR 6.5, 19.2) (Table 2).
We identified a total of 158 metabolites. In the univariate 
analysis we identified 20 metabolites with significant difference 
between pre- and post-peak concentrations (Table 3). 
Using SAM we identified 9 metabolites that were 
identified as significant using a delta of 0.6. The false 
discovery rate was 1.6%. All 9 covariates had a significant 
decrease in peak concentration after CT. Of the covariates, 2 
were not identified as known metabolites. In addition, 3 were 
noted to be amino acids, 2 were heterocylcic compounds, and 
1 was a breakdown product of carbohydrates. 
DISCUSSION
Alteration in renal function has been reported to occur in 
4-20% of patients undergoing CT angiograms of the chest and 
head. Contrast-induced nephropathy (defined as an increase of 
serum creatinine of 25% or higher within 2 days of receiving 
contrast or as a rise in plasma Cr of 0.5 mg/dL above baseline) 
is a leading cause of acute renal failure in this hospitalized 
patient population.12 Identification in the alteration in renal 
function is delayed when using serum creatinine as a marker 
of injury. In this study we were able to detect changes in 
urinary metabolites within 6 hours after the administration of 
intravenous contrast. 
This study provides the foundation to further evaluate 
the association of change in urinary metabolites and the 
development of CIN after CT imaging of the chest with 
contrast and identify specific metabolism pathways associated 
within the kidney after contrast administration. Intravenous 
contrast has been associated with renal toxicity. The 
mechanisms behind the development of CIN are complex. It 
has been suggested that the development of CIN is a result of 
the interplay of vasoconstriction, oxidative stress, and direct 
tubular toxicity leading to hypoxia of the outer medulla.13,14-15 
Numerous studies have reported on the effects of contrast 
media on various urinary enzymes and markers of glomerular 
and tubular function.16-20 The complex pathophysiology 
behind the renal effects of intravenous contrast provides the 
opportunity to identify multiple markers of potential renal 
injury.21 
After contrast dye administration there is a transient 
increase in renal blood flow followed by a decrease in renal 
blood flow due to vasoconstriction. This vasoconstriction 
Table 2. Demographics and patient characteristics.
Variable N (%) or mean (% or SD)
Age (median, IQR) 61 (50,68)
Male 9 (64.3)
Caucasian race 7 (50.0)
Smoker 8 (57.1)
Heart failure 5 (35.7)
Diabetes 6 (42.9)
Hypertension 11 (78.6)
Coronary artery disease 5 (35.7)
Heart rate bpm (median, IQR) 92.5 (79,112)
Systolic blood pressure mm/Hg 140 (119,157)
Serum creatinine mg/dL (median, 
IQR)
0.94 (0.83,1.14)
Serum BUN mg/dL (median, IQR) 13.5 (9,22)
48 hour change in creatinine mg/
dL (median, IQR)
0.02 (-0.04, 0.03)
Time since last meal hours 
(median, IQR)
11.2 (6.5, 19.2)
ED treatment
Diuretics 3 (23.1)
Steroids 2 (15.3)
Final diagnosis
Chest pain-not otherwise 
specified
6 (42.9)
Asthma/COPD 2 (15.4)
Heart failure 1 (7.7)
Other (pulmonary emboli, 
pneumonia, effusion)
5 (35.7)
BPM, beats per minute; IQR, interquartile range; BUN, blood urea 
nitrogen, ED, emergency department; COPD, chronic obstructive 
pulmonary disease
Table 1. Delta values and significant metabolites.
Delta Significant 
metabolites
False discovery 
rate
0.07 80 0.086
1.3 22 0.045
1.6 11 0.016
2.0 4 0.004
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may be mediated by adenosine, Angiotensin II or calcium. 
In addition, there appears to be direct damage to the kidney 
as a result of morphological alterations including proximal 
tubularvacuolar transformation, interstitial edema and tubular 
degeneration.22 
Studies have reported that ischemia from renal 
vasoconstriction causes cell sodium and chloride 
concentrations to rise, and cell potassium and phosphorus 
concentrations as well as cell dry weights to fall.21 These 
changes are most pronounced in the proximal straight tubule 
(PST) cells. PST show deranged electrolyte homeostasis for a 
prolonged period after injury.23 Amino acids such as glycine, 
alanine, and taurine have been shown to be protective to renal 
tubular cells when studied in vitro. In one study, the majority 
of amino acid derangements noted in the were PST cells 
were reversed except for low glycine contents in the cortex, 
whereas in the outer medulla aspartate, glycine and taurine 
contents were diminished.24 These results indicate increasing 
manifestation of PST cell injury in the reflow period. Studies 
have shown that as PST are injured there is a depletion of 
intracellular pools of amino acids as a result of injury to 
Na+ pump function. In injury there is also an alteration of 
catabolism of alanine and glutamate formation.25-26 We noted 
a decrease in glycine, n-(2-furanylcarbonyl)-in the urine, 
during our study. This raises the potential of amino acid 
supplementation as a potential nephrotoxicity protectant. 
We also reported a decrease in 5-hydroxymethlfurfural 
(HMF) levels after CT of the chest. HMF is largely formed 
by breakdown of hexoses such as glucose and fructose. It 
is bioactivated through sulfonation of its acyclic hydroxyl 
functional group to 5-sulfooxymethylfurfural (SMF). It can 
also be metabolized in the kidneys to 5-hydroxy-methyl-2-
furoic acid and other compounds such as glycine compounds 
in the kidney which are then secreted in the urine. The 
presence of HMF has been associated with nephrotoxicity 
in rats although never directly studied in humans.27 HMF is 
produced by the oxidation of sugars through decarboxylation, 
oxidation, dehydration and reduction. The exact mechanism of 
decreased elimination in the urine is unknown. 
In the kidney, adenosine locally activates adenosine 
A2 receptor and adjusts blood flow to meet demand. It is an 
intra-renal metabolite that accumulates in the kidney during 
renal ischemia. Elevated serum adenosine levels have been 
associated with a reduction in glomerular filtration rate 
(GFR). As GFR decreases there is an increase in sodium 
absorption further reducing GFR. In addition, adenosine is 
directly toxic to the renal cells. Our decline in urine adenosine 
may be due to the increase vasospasm and therefore renal 
ischemia associated with contrast administration.28 We also 
noted a decrease in the urinary metabolites of creatinine and 
cystine. Both of these metabolites are associated with the 
breakdown products of amino acids and are reabsorbed in the 
proximal tubule. It is possible that the reduction in GFR as a 
result of contrast dye leads to increased reabsorption of these 
metabolites. 
Prior studies have shown that the alteration of urinary 
concentration of metabolites that occurs as a result of toxic 
exposure is somewhat dependent on the toxic agent. For 
example, a study of nephrotoxicity as a result of HgCl 2 
treatment resulted in a decreased concentration of citrate 
and 2-oxoglutarate while acetate, succinate, and lactate were 
increased.29 These results are thought to be secondary to 
damage in the proximal tubule caused by this agent and the 
resulting uncoupling of oxidative phosphorylation. The injury 
to this area may result in alterations in loss of absorption 
capacity of amino acids. We also noted a decrease in urinary 
succinate levels in our study. However, unlike HgCl2-induced 
changes we also saw a reduction in alanine concentration. It 
has been suggested urinary changes in metabolites may be 
specific to different types of toxin-induced renal injury. It may 
be the overall pattern of the changes in urinary metabolites 
that can be used to identify early injury,rather than a single 
metabolite change.29 
LIMITATIONS
This is a pilot trial that was underpowered to detect an 
association of specific metabolites with CIN. The aim of the 
study was to evaluate urinary metabolite changes before and 
Table 3. Paired T test of log adjusted peak concentrations.
Peaks(mz/rt)* p.value -log10(p)
Furoylglycine 0.00123 2.90872
Unknown31& 0.00182 2.73956
Creatinine 0.00213 2.67232
Unknown28& 0.00548 2.26161
5-hydroxymethyl-2-furoic -acid 0.00586 2.23236
Levoglucosan 0.00599 2.2227
Cystine 0.01051 1.97832
Adenosine 0.01106 1.95643
Sucrose 0.01361 1.86613
Unknown34& 0.01609 1.79347
Glycerol-3-galactoside 0.01646 1.78365
Quinic acid 0.02317 1.63509
Palmitic acid 0.0237 1.62519
Taurine 0.02783 1.55552
Succinic acid 0.03123 1.50543
Idonic acid 0.04061 1.39138
hydroxypyridine 0.0421 1.37569
Deoxyribonic acid 0.04327 1.36383
Lactobionic acid 0.0449 1.34779
Glutamine 0.04787 1.31997
* mz/rt: specific mass-charge ratios (mz) /LC column retention 
times (RT)
&metabolites that were not identified were labelled “Unknown” 
followed by a numeric value
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after intravenous contrast. Given our sample size for this pilot 
project, we were not powered to detect changes in creatinine. 
Also related to the small sample size, we were unable to adjust 
for underlying medical illnesses, time since last meal, or base-
line renal function.
CONCLUSION
Diagnostic testing using CT is becoming routine in 
the ED. As the indications for this diagnostic modality 
increase, so does the potential increase in adverse events 
associated with this test procedure. CIN is a well-described 
complication of this diagnostic modality; however, current 
methods of identifying this disease are insensitive and 
require lengthy observation. In this study we have shown 
that there are changes in urinary metabolites within 6 
hours of CT imaging. It is therefore possible that urinary 
metabolites may be potential novel markers of renal injury. 
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